Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 602 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ILD Clear all
Completed Not applicable Interventional Results available

Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease

NCT01948518
View directory record Official record
Conditions
Diffuse Parenchymal Lung Disease, Pulmonary Hypertension
Interventions
Oral sildenafil 20 mg
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

NCT00468208
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 19, 2026, 5:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02633293
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 19, 2026, 5:45 AM EDT
Completed No phase listed Observational

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

NCT02055222
View directory record Official record
Conditions
Pulmonary Fibrosis, Lung Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

NCT01940094
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
5 mg Prednisone, 0 mg Prednisone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Terminated Not applicable Interventional

Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

NCT05359965
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Gastro Esophageal Reflux
Interventions
Positive Airway Pressure
Device
Lead sponsor
University of Arizona
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Not yet recruiting Phase 2 Interventional

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

NCT07674745
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 19, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

NCT06097260
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

NCT02579603
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pirfenidone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

NCT00080223
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
27
States / cities
Phoenix, Arizona • Pomona, California • San Jose, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 19, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lung Tissue Research Consortium

NCT02988388
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions
Lung biopsy/lobectomy
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT02345070
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SAR156597, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00600028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Cough
Interventions
Thalidomide, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

NCT03919435
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

NCT05890729
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
XTMAB-16 or Placebo
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

NCT02802345
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Placebo, Sildenafil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting No phase listed Observational

Analysis of Specimens From Individuals With Pulmonary Fibrosis

NCT00084305
View directory record Official record
Conditions
Pulmonary Fibrosis, Healthy Volunteers, Hermansky-Pudlak Syndrome (HPS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

NCT07047690
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Not listed Phase 3 Interventional

Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study

NCT00203697
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
minocycline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

NCT05867914
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
Inhaled Nitric Oxide (iNO)
Device
Lead sponsor
Third Pole Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Tampa, Florida • Cincinnati, Ohio • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

NCT01979952
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Matching Placebo, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 19, 2026, 5:45 AM EDT